PT3606546T - Constructo genético para utilização no tratamento de distúrbio neurodegenerativo ou acidente vascular cerebral - Google Patents

Constructo genético para utilização no tratamento de distúrbio neurodegenerativo ou acidente vascular cerebral

Info

Publication number
PT3606546T
PT3606546T PT187159116T PT18715911T PT3606546T PT 3606546 T PT3606546 T PT 3606546T PT 187159116 T PT187159116 T PT 187159116T PT 18715911 T PT18715911 T PT 18715911T PT 3606546 T PT3606546 T PT 3606546T
Authority
PT
Portugal
Prior art keywords
stroke
treatment
genetic construct
neurodegenerative disorder
neurodegenerative
Prior art date
Application number
PT187159116T
Other languages
English (en)
Original Assignee
Quethera Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Quethera Ltd filed Critical Quethera Ltd
Publication of PT3606546T publication Critical patent/PT3606546T/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Virology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Toxicology (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
PT187159116T 2017-04-05 2018-03-28 Constructo genético para utilização no tratamento de distúrbio neurodegenerativo ou acidente vascular cerebral PT3606546T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1705484.2A GB201705484D0 (en) 2017-04-05 2017-04-05 Genetic construct

Publications (1)

Publication Number Publication Date
PT3606546T true PT3606546T (pt) 2021-07-12

Family

ID=58682577

Family Applications (1)

Application Number Title Priority Date Filing Date
PT187159116T PT3606546T (pt) 2017-04-05 2018-03-28 Constructo genético para utilização no tratamento de distúrbio neurodegenerativo ou acidente vascular cerebral

Country Status (14)

Country Link
US (1) US20200046850A1 (pt)
EP (1) EP3606546B1 (pt)
JP (1) JP7296321B2 (pt)
KR (1) KR102616629B1 (pt)
CN (1) CN110809476B (pt)
AU (1) AU2018248651A1 (pt)
CA (1) CA3058549A1 (pt)
ES (1) ES2881176T3 (pt)
GB (1) GB201705484D0 (pt)
MX (1) MX2019012000A (pt)
PL (1) PL3606546T3 (pt)
PT (1) PT3606546T (pt)
RU (1) RU2757932C2 (pt)
WO (1) WO2018185468A1 (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113454227A (zh) * 2018-12-19 2021-09-28 维萨梅布有限公司 编码蛋白质的rna
US20220162572A1 (en) 2019-03-04 2022-05-26 Tokyo Metropolitan Institute Of Medical Science NUCLEIC ACID CONSTRUCT ENCODING Trk FRAGMENT AND USE THEREOF
BR112021019139A2 (pt) * 2019-03-27 2021-11-30 Sigilon Therapeutics Inc Célula de mamífero manipulada, composição, molécula isolada de dna de fita dupla, dispositivo implantável, cápsula de hidrogel, e, método de tratamento de um paciente com doença de fabry
GB202004832D0 (en) * 2020-04-01 2020-05-13 Instituto De Medicina Molecular Faculdade De Medicina Univ De Lisboa Therapeutic agaents, pharmaceutical compositions, and associated biomarkers
CN114933657B (zh) * 2021-08-25 2024-02-02 上海交通大学医学院 神经生长因子突变体重组蛋白及其应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2588221C (en) * 1999-06-08 2013-07-09 Regeneron Pharmaceuticals, Inc. Modified chimeric polypeptides with improved pharmacokinetic properties
US20030124095A1 (en) * 2001-12-31 2003-07-03 Regents Of The University Of California Methods for therapeutic use of brain derived neurotrophic factor in the entorhinal cortex
WO2009120978A2 (en) 2008-03-27 2009-10-01 The Ohio State University Treatment of metabolic-related disorders using hypothalamic gene transfer of bdnf and compositions therfor
CN102439041B (zh) * 2008-12-19 2016-05-04 H.隆德贝克有限公司 用于治疗精神和行为障碍的对Vps10p-结构域受体家族的调节
JP2015511494A (ja) * 2012-03-15 2015-04-20 キュアナ，インク． 脳由来神経栄養因子（ｂｄｎｆ）に対する天然アンチセンス転写物の阻害によるｂｄｎｆ関連の疾患の処置
GB2547179A (en) * 2015-10-26 2017-08-16 Quethera Ltd Genetic construct

Also Published As

Publication number Publication date
RU2757932C2 (ru) 2021-10-25
JP7296321B2 (ja) 2023-06-22
RU2019131098A (ru) 2021-05-05
CA3058549A1 (en) 2018-10-11
GB201705484D0 (en) 2017-05-17
KR102616629B1 (ko) 2023-12-21
EP3606546A1 (en) 2020-02-12
CN110809476A (zh) 2020-02-18
US20200046850A1 (en) 2020-02-13
CN110809476B (zh) 2024-02-27
EP3606546B1 (en) 2021-04-28
AU2018248651A1 (en) 2019-10-17
RU2019131098A3 (pt) 2021-07-27
JP2020516244A (ja) 2020-06-11
WO2018185468A1 (en) 2018-10-11
KR20200005549A (ko) 2020-01-15
ES2881176T3 (es) 2021-11-29
PL3606546T3 (pl) 2021-11-08
MX2019012000A (es) 2020-01-27

Similar Documents

Publication Publication Date Title
EP3227330C0 (en) TDP-43 BINDING POLYPEPTIDES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES
PL3157512T3 (pl) Zastosowanie kannabidioli w leczeniu padaczki
GB201411496D0 (en) Use of 7-Oh-Cannabidiol (7-Oh-CBD) and/or 7-Oh-Cannabidvarin (7-Oh-CBDV) in the treatment of epilepsy
PT3606546T (pt) Constructo genético para utilização no tratamento de distúrbio neurodegenerativo ou acidente vascular cerebral
IL264641A (en) Acetyl-leucine for use in the treatment of neurodegenerative diseases
GB201608885D0 (en) Treatment
PL3277280T3 (pl) Izomiosmina do zastosowania w leczeniu chorób autoimmunologicznych
GB201711190D0 (en) Use of cannabininoids in the treatment of a neurodegenerative disease or disorder
GB201608797D0 (en) Therapeutic use
SI3423060T1 (sl) Imatinib za uporabo pri zdravljenju možganske kapi
PT3160464T (pt) 6-hidroxibuspirona para uso no tratamento de transtornos do movimento
IL250182A0 (en) chlorinator
HK1209359A1 (en) Use of megamonas hypermegale in the treatment or prevention of rheumatoid arthritis or related diseases
GB201604316D0 (en) Combination therapy
PT3413870T (pt) Igmesina para utilização no tratamento de doença de alzheimer
GB201609735D0 (en) Combination therapy
HK1209357A1 (en) Use of dialister invisus in the treatment or prevention of rheumatoid arthritis or related diseases
GB201603653D0 (en) Combination Therapy
IL259383A (en) A compound for use in the prevention and treatment of neurodegenerative diseases
HK1209369A1 (en) Use of alistipes shahii in the treatment or prevention of rheumatoid arthritis or related diseases
PT3270913T (pt) Citalopram ou escitalopram para utilização no tratamento de doenças neurodegenerativas
HK1209364A1 (en) Use of actinomyces naeslundii in the treatment or prevention of rheumatoid arthritis or related diseases
HK1209367A1 (en) Use of clostridium nexile in the treatment or prevention of rheumatoid arthritis or related diseases
GB201617107D0 (en) Treatment
HK1209356A1 (en) Use of sutterella wadsworthensis in the treatment or prevention of rheumatoid arthritis or related diseases